Program
selcodebart
Its studies are mostly in Primary Myelofibrosis · Inflammatory Bowel Diseases · Renal Insufficiency, Chronic, led by Disc Medicine.
Furthest: phase 2, since Mar 15, 20224 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Disc Medicine | 42 open or running | phase 2since Mar 15, 2022 | Jul 20, 2021 | May 2027phase 2 · NCT05320198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2021First study: phase 1 study in Healthy VolunteerFirst studyNCT04999527 · 42 enrolled · United States
- Mar 15, 2022Phase 2 study in Primary MyelofibrosisNCT05320198 · 150 planned · United States, Australia
- Feb 16, 2023Phase 1 study in Renal Insufficiency, ChronicNCT05745883 · 55 enrolled · United States
- Jan 22, 2026Phase 2 study in Inflammatory Bowel DiseasesNCT07368972 · 21 planned · United States
Ahead
- May 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT05320198
TargetBeta
HJV →read by rule
“A humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07368972Inflammatory Bowel Diseases · United States | 2 | Recruiting | Oct 2026 | 21 |
| NCT05745883Renal Insufficiency, Chronic · United States | 1 | Completed | Oct 9, 2025 | 55 |
| NCT05320198Primary Myelofibrosis · United States, Australia | 2 | Recruiting | May 2027 | 150 |
| NCT04999527Healthy Volunteer · United States | 1 | Completed | Jun 30, 2022 | 42 |
How it is read
Names in the registry
- “DISC-0974”, 4 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 1 study
- Inflammatory Bowel Diseases, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.